The ‘new chemical entity’ patent no 2014358652 from Australia is valid through 2032, while that from the US will last till 2034, the company said.
The chemical is being studied for treating cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.
“The granted claims of the patents are from the mechanism of action include the class of selective 5HT6 and 5HT4 compounds and are being developed as therapeutic agents,” it said.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO of Suven.
Suven Life Science is a biopharmaceutical company engaged in developing new pharmaceutical products, especially in CNS therapies using GPCR targets.
Suven has four compounds in various phases of clinical trials — SUVN-502 in Phase 2, Phase 2 ready SUVN-G3031, and Phase 1 complete SUVN-D4010. The latest, SUVN-911, has just started Phase 1.
Phase 1 of clinical study focuses more on efficacy of the drug in treating the disease, followed by higher emphasis on long-term safety and so on in subsequent studies.
In addition to these clinical compounds the Company has nine internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain.